Name | CX717 |
---|---|
Synonyms |
2,1,3-Benzoxadiazol-5-yl(4-morpholinyl)methanone
Methanone, 2,1,3-benzoxadiazol-5-yl-4-morpholinyl- |
Description | CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD)[1][2]. |
---|---|
Related Catalog | |
In Vivo | CX 717 (CX717; 20 mg/kg) has a rapid (30 min) but short-lasting (up to 24 h) antidepressantlike effect in the forced swim test.CX 717 also produces a rapid (up to 1 h) increase of brain-derived neurotrophic factor (BDNF) and a more sustained (up to 6 h) increase of p11[2]. Intra-cortical infusion of CX 717 (85 mM) increases the efflux of noradrenaline, dopamine, and serotonin, but not glutamate[2]. Animal Model: Male Sprague-Dawley rats weighing 280-350 g[2] Dosage: 20 mg/kg (administered at 1 mL/kg) Administration: Intraperitoneal (i.p.) injection Result: Evoked antidepressant-like effects (20 mg/kg, i.p.) did not alter the extracellular concentrations of noradrenaline (NA), dopamine (DA), serotonin (5-HT) and glutamate in the medial prefrontal cortex (mPFC). |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 422.1±55.0 °C at 760 mmHg |
Molecular Formula | C11H11N3O3 |
Molecular Weight | 233.223 |
Flash Point | 209.1±31.5 °C |
Exact Mass | 233.080048 |
LogP | -0.64 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.623 |